Streetbeat News

Analyst Ratings

INZY

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:18 pm

BRKR

Wolfe Research has downgraded Bruker (NASDAQ:BRKR) from Outperform to Peer Perform, as per analyst Doug Schenkel.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:14 pm

FYBR

Wolfe Research has downgraded Frontier Communications from Outperform to Peer Perform, indicating a less favorable outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:13 pm

CMG

Oppenheimer analyst Brian Bittner has reiterated an Outperform rating on Chipotle Mexican Grill (NYSE:CMG) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:10 pm

AQST

Leerink Partners has reiterated its Outperform rating on Aquestive Therapeutics and raised the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:08 pm

CHTR

Wolfe Research has downgraded Charter Communications from Peer Perform to Underperform, setting a price target of $300.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:08 pm

BLFS

In the past three months, four analysts have rated BioLife Solutions (NASDAQ:BLFS), with a majority being bullish. The average 12-month price target has increased by 22.83% to $28.25. Despite positive analyst sentiment, BioLife faces financial challenges, including a decline in revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:01 pm

ALIT

In the past three months, six analysts have provided ratings for Alight (NYSE:ALIT), with a mix of bullish and neutral perspectives. The average 12-month price target has decreased by 13.64% to $9.5. Alight faces challenges with a 4.1% revenue decline, but maintains a strong net margin.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:01 pm

PR

16 analysts have provided varied opinions on Permian Resources (NYSE:PR) over the past quarter, with a mix of bullish and somewhat bullish ratings. The average 12-month price target has declined by 5.63% to $18.94. Analysts have adjusted their ratings and price targets in response to market dynamics, with some lowering their targets. Permian Resources has shown strong financial performance with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm

ELF

e.l.f. Beauty (NYSE:ELF) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has decreased by 4.44% to $212.67. Despite a smaller market capitalization, e.l.f. Beauty has shown strong financial performance with a 49.99% revenue growth rate, a 14.66% net margin, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 12:00 pm